Andere Sprachen Daiichi Sankyo Co., Ltd.

Aktien

A0F57T

JP3475350009

4568

Verzögert Japan Exchange Andere Börsenplätze 07:00:00 04.12.2023			% 5 Tage	% 1. Jan.
4.025 ^JPY	-2,09 %		-1,03 %	-5,29 %

04.12.	DAIICHI SANKYO CO., LTD. : Von Jefferies & Co. zum Kauf angehoben	ZM
27.11.	Japanisches Gremium empfiehlt Zulassung der aktualisierten COVID-Impfung von Daiichi Sankyo - Kyodo	RE

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH	04.12.
Daiichi Sankyo - DAICHIRONA FOR INTRAMUSCULAR INJECTION for Booster Vaccination Approved in Japan as Omicron XBB.1.5-adapted monovalent mRNA Vaccine against COVID-19	29.11.
Japan OKs 1st home-grown COVID shots tailored for Omicron subvariant	28.11.
Japan panel recommends approval of updated Daiichi Sankyo COVID shot- Kyodo	27.11.
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings	27.11.
Daiichi Sankyo Wins Favorable Final Arbitration Ruling in Dispute with Seagen	21.11.
Daiichi Sankyo Reaches Agreement with MHLW to Supply Omicron XBB.1.5-adapted COVID-19 Vaccine in Japan	20.11.
Japan to buy 1.4 mln doses of Daiichi Sankyo COVID vaccine	17.11.
IHH Healthcare Unit Pursues Legal Action Against Daiichi Sankyo Over Fortis Deal	14.11.
IHH Healthcare unit sues Japan's Daiichi Sankyo over Fortis deal	14.11.
Shiseido Shares Tumble as Worsening China Business Prompts Guidance Cut	13.11.
Daiichi Sankyo - VANFLYTA Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML	10.11.
Targeted therapy for hard-to-treat leukaemia subtype approved in EU	09.11.
AstraZeneca ups guidance; inks licence deal for obesity drug	09.11.
MARKET CHATTER : export prodotti ittici Giappone verso Cina crolla del 90,8%	09.11.
VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML	09.11.
Daiichi Sankyo Company, Limited's VANFLYTA (quizartinib) Approves in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML	09.11.
Japan's Seafood Exports to China, Falls 90.8% to 800 million Yen in September	09.11.
Pharmacie : challenge pour les Big Pharma	08.11.
Fukushima: début de la 3e phase de rejet de l'eau de la centrale accidentée	02.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Daiichi Sankyo Co., Ltd.

Aktien

A0F57T

JP3475350009

4568

Andere Sprachen

Filter